Semax — Literature-Reported Ranges & Study Protocols

Read this first

Every figure on this page is a range reported in published literature or in a publicly documented study protocol. It is a record of what researchers used, not a recommendation, a therapeutic protocol, or advice. Peptide Intel Hub is an independent publication, sells nothing, and describes these compounds as in-vitro research reagents only.

Compound at a glance

Class: ACTH(4-10) analogue heptapeptide
Reported half-life: Minutes systemically; nasal administration is used to bypass this
Routes used in the literature: Intranasal in nearly all published work
Also written as: —

What the published studies reported

Each row below describes one body of work. The model and population are part of the figure — a rodent per-kilogram quantity and a human trial quantity are not comparable.

Ischaemic stroke studies

Reported quantity: 12–18 mg per day of the 1% intranasal solution in the acute arms
Frequency: Divided across the day
Study duration: 10 days

The higher acute-stroke figures are much larger than the cognitive-performance arms.

Cognitive and attention studies

Reported quantity: Around 100–600 µg per day using the 0.1% solution
Frequency: Two to three administrations daily
Study duration: 3–14 days

The 0.1% and 1% formulations differ tenfold — the percentage is the critical detail.

Dosage chart

These figures match the published chart for this compound on peptidedosages.com, including the reconstitution volume, resulting concentration, insulin-syringe units and the staged schedule. Educational reference only — not instructions, and not medical advice.

Semax · 10 mg Vial

This Semax dosage chart explains how a 10 mg vial can be calculated for intranasal research with a verified 0.10 mL metered actuator. Published human Semax studies primarily used intranasal drops or measured intranasal solution. A measured 5 mL final volume provides 200 mcg per spray, while a measured 10 mL final volume provides 100 mcg per spray.

Primary human research route: Intranasal drops or measured intranasal solution.
5 mL final volume: 2 mg/mL, 200 mcg per verified 0.10 mL spray, and 50 nominal sprays.
10 mL final volume: 1 mg/mL, 100 mcg per verified 0.10 mL spray, and 100 nominal sprays.
Device check: Confirm the pump output and follow its priming instructions before using the calculation.
Research context: Published amounts varied by study population, formulation, and research objective.

# Research Amount to Spray Equivalents

Measured Final Volume	Vehicle Added After Transfer	Final Concentration	Per Verified 0.10 mL Spray
5.0 mL	About 2.0 mL	2,000 mcg/mL	200 mcg<br>50 nominal sprays
10.0 mL	About 7.0 mL	1,000 mcg/mL	100 mcg<br>100 nominal sprays

Source chart on peptidedosages.com

Mixed with 3 ml of bacteriostatic water

The same arithmetic for every vial size Semax is supplied in, using a fixed 3 ml of bacteriostatic water. One unit on a U-100 insulin syringe is 0.01 ml, so the unit column below is simply the volume that carries the reported amount. Educational arithmetic only — not instructions, and not medical advice.

Semax · 3 ml bacteriostatic water

Vial size	Concentration	Per 1 unit
5 mg	1.67 mg/ml	17 mcg
10 mg	3.33 mg/ml	33 mcg

No single reported amount applies to this compound, so only the concentration and the value of one unit are shown. Only the vial sizes this compound is actually supplied in are shown, and every figure assumes exactly 3 ml of bacteriostatic water. For any other volume, use the reconstitution calculator.

Reconstitution maths

A 30 mg vial in 3 mL gives a 1% solution; the same vial in 30 mL gives 0.1%. Check which concentration the study you are reading used.

Open the reconstitution calculator

How to read these figures

Formulation percentage, not vial mass, determines what the published figures mean.
BDNF upregulation is the most cited proposed mechanism.
Effectively all evidence originates from a single national research tradition.

Sources and citations

These are the published records the figures on this page are drawn from. Each one describes what researchers administered, in which model or population, and over what period. Quantities reported in a study are specific to that study's design and are not transferable guidance.

[1]
The efficacy of semax in the treatment of patients at different stages of ischemic stroke
Gusev EI, Martynov MY, Skvortsova VI, et al. · Zh Nevrol Psikhiatr Im S S Korsakova · 2005 · PMID 29798983 (EuropePMC)
Ischemic stroke patients received intranasal Semax (0.1% solution, at doses reported in the range of 12-18 mg/day) during acute and subacute stages to assess neurological recovery.
View the record
[2]
Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)
Skvortsova VI, et al. · Zh Nevrol Psikhiatr Im S S Korsakova · 1999 · PMID 11517472
Patients with acute hemispheric ischemic stroke were administered intranasal Semax within the first hours of stroke onset to evaluate clinical and electrophysiological outcomes.
View the record

Search the databases yourself

Read the Semax research brief

Other cognitive compounds

CerebrolysinPorcine brain-derived peptide preparation DihexaAngiotensin IV analogue, HGF/c-Met potentiator DSIPNonapeptide PE-22-28Spadin analogue, TREK-1 channel blocker

All research protocols

Peptide Intel Hub is an independent publication and has no affiliation, ownership or commercial relationship with the suppliers listed. We sell nothing and take no payments — links are editorial references only.